The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Maria Luisa Limon
No Relationships to Disclose
 
Ka Yeung Mark Wong
Consulting or Advisory Role - MSD Oncology
Speakers' Bureau - MSD Oncology; Sirtex Medical
 
Alain Hendlisz
No Relationships to Disclose
 
Massimo Aglietta
No Relationships to Disclose
 
Pilar Garcia-Alfonso
Consulting or Advisory Role - Amgen; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER
Speakers' Bureau - Amgen; Merck Serono; MSD Oncology; Pierre Fabre; Sanofi; SERVIER
 
Bart Neyns
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre
 
Fabio Gelsomino
No Relationships to Disclose
 
Dana Backlund Cardin
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Clarivate; the KOL Connection Ltd
Research Funding - Array BioPharma (Inst); Corcept Therapeutics (Inst); Elicio Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); XBiotech (Inst)
 
Tomislav Dragovich
Research Funding - ARMO BioSciences; Berg Pharma; Bristol-Myers Squibb (Inst); Halozyme (Inst); HolyStone Therapeutics (Inst); Kyowa Hakko Kirin; Medivir; Novocure (Inst); Rgenix
 
Usman Shah
No Relationships to Disclose
 
Stephen McCraith
No Relationships to Disclose
 
Rui Wang
No Relationships to Disclose
 
Ming Lei
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
Patents, Royalties, Other Intellectual Property - Inventor of pending BMS patents
 
Jin Yao
No Relationships to Disclose
 
Lixian Jin
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene
 
Sara Lonardi
No Relationships to Disclose